Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

Download PDF File

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

Download PDF File (382 Ko)

Theranexus announces that Rodolphe Besserve will join its Board of Directors

Download PDF File (368 Ko)

Theranexus announces a new European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers

Download PDF File (373 Ko)

 Recognition of the scientific excellence of Theranexus

Download PDF File (379 Ko)

Theranexus announces its first half 2018 results

Download PDF File (335 Ko)